

## THORACIC CANCER PROGRAM OVERVIEW

MSK's thoracic cancer program is recognized as one of the world's finest,



**ranked fifth out of 51 top-scoring hospitals for urology in U.S. News & World Report.**

We provide patients with:

- the latest minimally invasive, image-guided techniques for the diagnosis and treatment of lung cancer, esophageal cancer, mesothelioma, thymoma, and cancer that has spread to the lungs.
- the benefit of seeing multiple specialists on one day, in one location
- an individualized treatment and recovery plan
- a comprehensive risk assessment and long-term surveillance program
- access to innovative clinical trials of chemotherapies, surgical techniques, and advanced technologies that are not available at other hospitals
- genomic sequencing

## LOCATIONS

Many of our specialists are centrally located at our **Manhattan location**. We also have regional outpatient locations at:

- MSK Basking Ridge, New Jersey
- MSK Bergen, New Jersey
- MSK Monmouth, New Jersey
- MSK Commack, New York
- MSK Rockville Centre, New York
- MSK Westchester, West Harrison, New York

**Sign up for OncoNotes**, MSK's clinical updates newsletter.

Go to [MSKCC.org](http://MSKCC.org), click on the **For Health Professionals** section, and choose "Sign up for Our E-newsletter."

### Our Team Leaders

**Charles Rudin**, MD, PhD  
Co-Director, Druckenmiller Center for Lung Cancer Research; Sylvia Hassenfeld Chair in Lung Cancer Research

**David Jones**, MD  
Co-Director, Druckenmiller Center for Lung Cancer Research; Fiona and Stanley Druckenmiller Chair in Lung Cancer

**Stephen Solomon**, MD  
Chief, Interventional Radiology Service

**Marc Ladanyi**, MD  
William J. Ruane Chair in Molecular Oncology

**Daniela Molena**, MD  
Director, Esophageal Surgery Program

**William Travis**, MD  
Director, Thoracic Pathology

### REFER A PATIENT

Contact our Physician Access  
Service directly at

**800-525-2225**

MSK has insurance contracts with most major health plans in the New York tristate area.



# Thoracic Cancer Program



Memorial Sloan Kettering  
Cancer Center



Memorial Sloan Kettering  
Cancer Center




## WHY CHOOSE MSK FOR THORACIC CANCER CARE?

### Expertise

- We are the first hospital in the United States to create a **dedicated advanced thoracic cancer team**. Our morbidity and mortality rates are among the lowest in the country.
- Our surgical expertise and high volumes allow us to perform **thoracic and esophageal surgeries** on people who are not surgical candidates elsewhere.
- Our **lung-sparing surgical program** for thoracic cancer is globally recognized.

### By the Numbers



### Leadership

- Our specialists have **expertise in specific types of cancer**, including *KRAS* and *BRAF* mutations, squamous cell lung cancer, and mesothelioma.
- We have some of the world's most extensive experience with radiation therapy before and after esophageal cancer surgery.
- We have more than **60 thoracic clinical trials underway** for a broad range of targeted therapies and immunotherapy agents, and a phase I chimeric antigen receptor T cell therapy trial for mesothelioma and malignant pleural disease.

### Advanced Technologies

- We perform a large volume of minimally invasive procedures using video-assisted or robotic surgical techniques, resulting in **greater precision, fewer complications, and decreased postoperative pain** compared with open surgery.
- Our **enhanced recovery program** results in shorter hospital stays and faster recovery times.
- We routinely utilize **MSK-IMPACT™** to **test for more than 400 mutations in both rare and common cancers** and **match tumors with targeted therapies**.
- Our **24-7 pathology lab** processes digitized images of tissue samples very quickly, including during surgery, to help patients avoid unnecessary procedures.